Hill-Rom Holdings Inc (NYSE:HRC) Downgraded to “Hold” at Zacks Investment Research

Hill-Rom Holdings Inc (NYSE:HRC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday, November 7th.

According to Zacks, “Hill-Rom exited fiscal 2017 on a strong note with fourth-quarter earnings and revenues beating the Zacks Consensus Estimate. The company saw a solid year-over-year increase in revenues on strong international growth. Hill-Rom is currently focused on gaining traction in the untapped international market on successful execution of the company’s strategy, courtesy its efficient international team and organizational realignment. The company is focusing on product innovation through research and development. A slew of product launches in the fourth quarter is encouraging. Moreover, an improvement in adjusted and operating margin buoys optimism. However, a decline in revenues at the Patient Support Systems segment is quite disappointing. Also, foreign exchange and a tough competitive landscape remain headwinds.Overall, Hill-Rom has underperformed the broader industry in the last six months.”

Other equities analysts have also recently issued reports about the stock. KeyCorp restated a “buy” rating and issued a $82.00 target price on shares of Hill-Rom in a research report on Tuesday, October 17th. Needham & Company LLC dropped their target price on shares of Hill-Rom from $95.00 to $93.00 and set a “buy” rating for the company in a research report on Friday, July 28th. BidaskClub cut shares of Hill-Rom from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 24th. Stifel Nicolaus restated a “buy” rating and issued a $84.00 target price on shares of Hill-Rom in a research report on Sunday, July 30th. Finally, ValuEngine cut shares of Hill-Rom from a “buy” rating to a “hold” rating in a research report on Saturday, November 4th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Hill-Rom has a consensus rating of “Buy” and an average target price of $88.57.

Shares of Hill-Rom (HRC) opened at $83.53 on Tuesday. The company has a debt-to-equity ratio of 1.55, a quick ratio of 1.34 and a current ratio of 1.77. The company has a market cap of $5,498.03, a PE ratio of 21.64, a P/E/G ratio of 1.78 and a beta of 1.19. Hill-Rom has a twelve month low of $52.58 and a twelve month high of $84.65.

Hill-Rom (NYSE:HRC) last posted its quarterly earnings data on Friday, November 3rd. The medical technology company reported $1.32 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.27 by $0.05. The firm had revenue of $738.30 million during the quarter, compared to the consensus estimate of $731.10 million. Hill-Rom had a net margin of 4.87% and a return on equity of 20.27%. The business’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.18 EPS. analysts forecast that Hill-Rom will post 4.26 earnings per share for the current fiscal year.

In related news, SVP Andreas G. Frank sold 6,870 shares of the stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $77.48, for a total transaction of $532,287.60. Following the transaction, the senior vice president now directly owns 16,701 shares of the company’s stock, valued at $1,293,993.48. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Andreas G. Frank sold 3,940 shares of the stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $77.84, for a total transaction of $306,689.60. Following the transaction, the senior vice president now directly owns 16,701 shares in the company, valued at $1,300,005.84. The disclosure for this sale can be found here. Corporate insiders own 2.20% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of HRC. Wellington Management Group LLP boosted its stake in Hill-Rom by 129.2% during the first quarter. Wellington Management Group LLP now owns 20,776 shares of the medical technology company’s stock worth $1,467,000 after acquiring an additional 11,712 shares in the last quarter. Credit Suisse AG boosted its stake in Hill-Rom by 0.5% during the first quarter. Credit Suisse AG now owns 118,010 shares of the medical technology company’s stock worth $8,331,000 after acquiring an additional 576 shares in the last quarter. Public Employees Retirement System of Ohio boosted its stake in Hill-Rom by 2.8% during the first quarter. Public Employees Retirement System of Ohio now owns 39,419 shares of the medical technology company’s stock worth $2,783,000 after acquiring an additional 1,057 shares in the last quarter. Independent Portfolio Consultants Inc. boosted its stake in Hill-Rom by 171.5% during the second quarter. Independent Portfolio Consultants Inc. now owns 1,344 shares of the medical technology company’s stock worth $107,000 after acquiring an additional 849 shares in the last quarter. Finally, Capstone Asset Management Co. boosted its stake in Hill-Rom by 2.4% during the second quarter. Capstone Asset Management Co. now owns 7,695 shares of the medical technology company’s stock worth $613,000 after acquiring an additional 180 shares in the last quarter. 80.37% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Hill-Rom Holdings Inc (NYSE:HRC) Downgraded to “Hold” at Zacks Investment Research” was reported by BBNS and is the property of of BBNS. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://baseballnewssource.com/markets/hill-rom-holdings-inc-hrc-downgraded-to-hold-at-zacks-investment-research/1764728.html.

Hill-Rom Company Profile

Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.

Get a free copy of the Zacks research report on Hill-Rom (HRC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc and related companies with our FREE daily email newsletter.

 


Latest News

Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Manny Machado Could Change Positions or Uniforms
Manny Machado Could Change Positions or Uniforms
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot


Leave a Reply

 
© 2006-2017 BBNS.